Evidence map›Paper›PMID 37284974›Full record

ArticleClinical pharmacokinetics2023

Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment.

Hengli Zhao, Zhirui Zhao, Kun He, Nianrong Mi, Kai Lou, Xiaolin Dong, Wenyu Zhang, Jingfang Sun, Xinyu Hu, Shuguang Pang and 2 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Hengli Zhao *Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China.
Zhirui Zhao *Department of Renal Division, Beijing Anzhen Hospital, Capital Medical University, No.2 Anzhen Street, Chaoyang District, Beijing, 100029, People's Republic of China.
Kun HeDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China.
Nianrong MiDepartment of Endocrinology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China.
Kai LouDepartment of Endocrinology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China.
Xiaolin DongDepartment of Endocrinology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China.
Wenyu ZhangDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China.
Jingfang SunJilin Huisheng Biopharmaceutical Co., Ltd., Jilin, 135000, People's Republic of China.
Xinyu HuJilin Huisheng Biopharmaceutical Co., Ltd., Jilin, 135000, People's Republic of China.
Shuguang PangDepartment of Endocrinology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China. shuguangpang@163.com.
Hong ChengDepartment of Renal Division, Beijing Anzhen Hospital, Capital Medical University, No.2 Anzhen Street, Chaoyang District, Beijing, 100029, People's Republic of China. drchengh@163.com.
Qing WenDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Li Xia District, Jinan, 250013, People's Republic of China. wenq0619@126.com.ORCID http://orcid.org/0000-0002-6408-2370
Jinan Central Hospital · CNCapital Medical University · CNHealth Commission of Jilin Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundJanagliflozin is a novel sodium-glucose cotransport-2 inhibitor. Despite its remarkable effect in glycemic control, no systematic research has evaluated the effect of renal impairment (RI) on its pharmacokinetics and pharmacodynamics.

methodsHere, patients with T2DM (n = 30) were divided into normal renal function (eGFR ≥ 90 mL/min/1.73 m

resultsFollowing oral administration, janagliflozin was rapidly absorbed, with the time to C

conclusionsThe exposure levels of janagliflozin in T2DM patients were slightly increased with worsening of RI (i.e., 11% increase in the AUC in patients with moderate RI compared with the normal renal function group). Despite worsening of renal function, janagliflozin exerted a significant pharmacologic effect and was well tolerated, even in patients with moderate RI, implying a promising role in the treatment of patients with in T2DM. REGISTRATION: China Drug Trial register ( http://www.chinadrugtrials.org.cn/I ) identifier no.: CTR20192721.

Indexed as

Diabetes Mellitus, Type 2Renal InsufficiencyXylitolCyclohexenesEast Asian PeopleGlucoseHumansCyclohexenesGlucosejanagliflozinXylitol

Identifiers

PMID37284974
OpenAlexW4379599619

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.